Skip to main content

View full-text article in PMC

. 2009 Jul 7;15(25):3134–3141. doi: 10.3748/wjg.15.3134

Table 2.

Effect of extraintestinal manifestations on serum bile acids and conjugates in UC cohorts (nmol/L)

BA class	BA/BA-conjugate	Control	No EM	Arthralgia/arthritis	Hepatobiliary diseases
Primary	CA	62.5	67.5	88.5	59.0
	TCA	23.6	0.0	0.0	67.9^b ^c
	GCA	383.5	360.0	408.5	722.5^a ^b
	CDCA	196.5	37.5	175.5	252.0
	TCDCA	230.5	140.0^a	92.5^a	163.0^c
	GCDCA	1446.0	1327.0	1281.5	2403.0^b ^c
Secondary	DCA	239.8	78.0^a	28.0^a	62.5^a
	TDCA	48.2	0.0^a	0.0^a	0.0^a
	GDCA	38.6	82.2^a	14.0^a	131.7^c
	LCA	15.0	8.0^a	6.1^a	18.0^b ^c
	TLCA	0.0	0.0^a	0.0^a	0.0
	GLCA¹	17.4	2.0^a	0.0	6.5
	UDCA	28.5	18.0^a	7.0^a ^b	131.5^b ^c
	TUDCA	0.0	0.0	0.0^a ^b	30.9^a ^b ^c
	GUDCA¹	137.9	96.5	54.1	75.1
Tertiary	HDCA	0.0	9.5^a	8.0^a	28.0^a
	THDCA	0.0	0.0^a	0.0	0.0
	GHDCA¹	0.0	0.0	0.0	0.0

Control: n = 310; No EM: n = 50, n = 21¹; Arthralgia/arthritis: n = 30, n = 7¹; Hepatobiliary diseases: n = 16, n = 6¹. Data expressed as medians.

^a

P < 0.05 vs control,

^b

P < 0.05 vs no EM,

^c

P < 0.05 vs arthralgia/arthritis (Mann-Whitney U test).